Generic Name and Formulations:
Edaravone 30mg/100mL; soln for IV infusion; contain sulfites.
Mitsubishi Tanabe Pharma America
Indications for RADICAVA:
Amyotrophic lateral sclerosis (ALS).
Give as IV infusion over 60mins. Initial cycle: 60mg (given as two consecutive 30mg infusions) daily for 14 days, followed by 14 days off. Subsequent cycles: 60mg daily for 10 days out of 14-day periods, followed by 14 days off.
Monitor for hypersensitivity reactions; discontinue and treat if occur. Asthma. Sulfite sensitivity. Pregnancy. Nursing mothers.
Free radical scavenger.
Confusion, gait disturbance, headache, dermatitis, eczema, respiratory failure/disorders, hypoxia, glycosuria, tinea infection; hypersensitivity reactions, anaphylaxis.
Single-dose bags—1, 2
Neurology Advisor Articles
- Gender and Multiple Sclerosis: How It Influences Prognosis and Future Treatment
- Natalizumab Improves Cognitive Function in Multiple Sclerosis
- Significant Variations in Epilepsy Surgical Strategy, Deficit Reporting Exist
- Thrombolysis With Tenecteplase Is as Safe as Alteplase in Stroke Mimics
- Smoking Promotes Disease Progression in Multiple Sclerosis
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- Deep Brain Stimulation Reduces Tremor Symptoms in Parkinson Disease
- FDA Issues Statement Addressing Safety Concerns Associated With Nuplazid
- Prevalence of Autoimmune Encephalitis in Herpes Simplex Encephalitis Explored
- Chronic Cluster Headaches Improve With High-Volume Suboccipital Nerve Blocks
- Multiple Sclerosis Increases Risk for Infection During Pregnancy